Clincosm LogoSign in Get a demo

Clinical Study of QSOX1 as a Biomarker for Colon Cancer

Sponsor
Qianfoshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05827471
Collaborator
(none)
400
Enrollment
42
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Diagnosis of colon cancer

Detailed Description

The project mainly selects the tumor group represented by colon cancer and the corresponding healthy people as the control group, with about 100 cases in each of the two groups. Mainly collect blood and tumor tissue samples of patients, detect the expression of QSOX1 in the above samples, and explore the role in the diagnosis and prognosis evaluation of colon cancer.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2026
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Tumor group

First diagnosis of colon cancer.

Diagnostic Test: Diagnosis of colon cancer
Clinical diagnosis results
Control group

Healthy people.

Diagnostic Test: Diagnosis of colon cancer
Clinical diagnosis results

Outcome Measures

Primary Outcome Measures

  1. Detection of RNA for early rapid diagnosis of colon cancer. [6 months]

    RT-PCR was used to detect the RNA levels of QSOX1 in the tumor and control groups.

  2. Detection of protein for early rapid diagnosis of colon cancer. [6 months]

    Western blotting was used to detect the protein levels of QSOX1 in the tumor and control groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Colon cancer was confirmed by colonoscopic pathology.

  • No local or systemic treatment was performed before operation.

  • Complete clinical data.

Exclusion Criteria:

  • Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp.

  • Other tumors other than colon cancer.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Qianfoshan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
YunqiuWang, Dr, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT05827471
Other Study ID Numbers:
  • QianfoshanHwyq20230305
First Posted:
Apr 25, 2023
Last Update Posted:
Apr 25, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Colonic Neoplasms

Study Results

No Results Posted as of Apr 25, 2023